Stay updated with breaking news from Multiple Ascending Dose. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Regulus Therapeutics Inc. (RGLS) saw an 8% increase in its shares on Wednesday after announcing the completion of patient enrollment in the second cohort of the Phase 1b Multiple-Ascending Dose (MAD) study of RGSL8429 for treating Autosomal Dominant Polycystic Kidney Disease (ADPKD).
AlzeCure Publishes the Positive Clinical Results from the Phase I Trial ...
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
/PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic...
Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B, measured during oral glucose tolerance testing (OGTT),